Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment.

JCO precision oncology - 1 Nov 2021

Popat Sanjay, Sharma Bhupinder, MacMahon Suzanne, Nicholson Andrew G, Sharma Rajaei K, Schuster Klaus, Lang Lazdunski Loic, Fennell Dean

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Mesothelioma, Malignant
Share to Mutation
Share to Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patched-1 Receptor

Share to Positron Emission Tomography Computed Tomography

Share to Pyridines

Source

Identifiers

PMID: 34994590
DOI: 10.1200/PO.20.00260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment.PMID 34994590Read ↗

Integrated genomics identify novel immunotherapy targets for malignant mesotheliomaSemantic proximity Read ↗

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.Semantic proximity Read ↗

Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR InhibitionSemantic proximity Read ↗

microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesotheliomaSemantic proximity Read ↗

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatmentSemantic proximity Read ↗

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of MesotheliomaSemantic proximity Read ↗

ERCC1, MLH1, MSH2, MSH6, and βIII-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural MesotheliomaSemantic proximity Read ↗

CDKN2A Determines Mesothelioma Cell Fate to EZH2 InhibitionSemantic proximity Read ↗

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.Semantic proximity Read ↗

P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced MesotheliomaSemantic proximity Read ↗

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.Semantic proximity Read ↗

Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.